Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma (BBIO) reported new exploratory Phase 3 PROPEL 3 data showing that 52 weeks of oral infigratinib in children with achondroplasia led to favorable trends versus placebo in sleep apnea, ear infections, and body composition.
Mean total Apnea-Hypopnea Index increased 10.4% with infigratinib versus 49.2% with placebo, and was unchanged versus a 63.2% increase in placebo among children under 8. The annualized otitis media rate was 38% lower with infigratinib versus placebo, and 47% lower in children under 8. Body composition analyses showed smaller BMI increases and lower gains in fat and visceral fat, with greater lean mass gain versus placebo.
Across up to three years of PROPEL treatment, height Z-score improved by +0.92 SD and upper-to-lower body ratio by -0.15, with no new safety signals. BridgeBio has submitted an NDA to the FDA, anticipates a potential U.S. launch in mid-2027, and plans an EMA MAA in Q4 2026.
BridgeBio Pharma (BBIO) will present new data on oral infigratinib in achondroplasia at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026 in Marseille, France, on September 8–10, 2026.
The company highlights a late-breaking oral presentation from the randomized PROPEL 3 trial evaluating oral infigratinib’s impact on medical complications in children with achondroplasia, to be delivered by Julie Hoover-Fong, M.D., Ph.D., on September 9 at 10:00 am CEST. Two posters will cover longer-term efficacy and safety data and the PROPEL Infant & Toddler Phase 2/2b study in children under 3 years old, alongside an ePoster on medical challenges and functional impacts of hypochondroplasia. Oral infigratinib is described as an investigational FGFR3 inhibitor intended to improve bone growth in skeletal dysplasias such as achondroplasia and hypochondroplasia.
BridgeBio (Nasdaq: BBIO) announced that its management team will participate in several healthcare investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Morgan Stanley, and Bernstein in Boston and New York on dates between September 9 and September 23.
Live webcasts of the fireside chats will be available via the Investors “Events and Presentations” page on BridgeBio’s website, with replays accessible for 90 days. BridgeBio describes itself as a commercial-stage biopharmaceutical company developing medicines for genetic conditions using a decentralized hub-and-spoke model.
BridgeBio (Nasdaq: BBIO) announced a voluntary agreement with the U.S. government aimed at expanding access to its medicines, especially for Medicaid patients, while lowering costs for American patients. Under the deal, BridgeBio will expand state Medicaid access to its currently marketed medicine via the GENEROUS Model.
According to BridgeBio, Attruby will continue to be offered via Medicare Part D without future pricing mandates, and the ForgingBridges copay assistance program remains unchanged, potentially reducing out-of-pocket costs to as little as $0 per month for qualifying patients. The company also highlighted three additional medicines under FDA review for rare genetic conditions.
BridgeBio Pharma (Nasdaq: BBIO) reported new Phase 3 ATTRibute‑CM analyses for Attruby (acoramidis) in transthyretin amyloid cardiomyopathy (ATTR‑CM), showing CMR‑based evidence that long‑term treatment can potentially reverse cardiac structural disease progression and functional decline through 42 months in a substantial subset of patients.
In the CMR completer analysis, clinically meaningful improvement in left ventricular systolic function was seen in 54% of acoramidis‑treated patients versus 20% on placebo at Month 30, with 53% improvement at Month 42 in continuous‑treatment patients. A conservative analysis showed improvement in roughly one‑third of treated patients and favorable LV mass remodeling.
A post‑hoc analysis found acoramidis reduced days lost to death or cardiovascular hospitalization and preserved an additional 38 days alive and out of hospital over 30 months, increasing to 65 observed and up to 94 modeled days over three years. In the open‑label extension through Month 54, continuous acoramidis in variant ATTR‑CM, including p.Val142Ile carriers, was associated with markedly lower all‑cause and cardiovascular mortality versus placebo‑to‑acoramidis, durable biomarker effects, improved quality of life and heart‑failure status, and a generally well‑tolerated safety profile.
BridgeBio (Nasdaq: BBIO) reported dosing the first participant in ASCEND-ATTR, a Phase 3b/4, single-arm, open-label study evaluating long-term treatment with acoramidis (Attruby) in adults with transthyretin amyloid cardiomyopathy (ATTR-CM). The trial aims to further characterize improvement in cardiac structure, function, and amyloid burden.
According to BridgeBio, ASCEND-ATTR will enroll about 150 participants, using annual cardiovascular magnetic resonance (CMR) and echocardiography over 36 months. The primary endpoint is Month 36 CMR responder status based on improved left ventricular systolic function, with secondary endpoints including additional imaging, biomarkers, and amyloid burden. Prior ATTRibute-CM CMR substudy data suggested improvements in LVMi, LVSVi, LVEF and amyloid regression in a subset of patients, supporting this long-term evaluation of acoramidis, a selective, orally administered near-complete (≥90%) TTR stabilizer. Attruby is already indicated to treat ATTR-CM in adults to reduce cardiovascular death and related hospitalizations.
BridgeBio (Nasdaq: BBIO) will present two oral presentations and three posters on new acoramidis data in transthyretin amyloid cardiomyopathy (ATTR-CM) at the ESC Congress 2026 in Munich on August 28–31, 2026. These include open-label extension analyses from the ATTRibute-CM study, covering survival, hospitalization days, myocardial structure/function, and patient-reported outcomes in wild-type and variant ATTR-CM.
In partnership with Yale’s Cardiovascular Data Science Lab, three additional moderated ePosters will highlight AI-driven approaches for ATTR-CM, including a digital biomarker AI-ECG, a decentralized digital registry, and a nationwide multimodal screening network. Acoramidis is marketed as Attruby and BEYONTTRA, indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM. Diarrhea and upper abdominal pain were the most common adverse reactions versus placebo, with similar discontinuation rates.
BridgeBio Pharma (Nasdaq: BBIO) announced the pricing of a secondary offering of 5,000,000 shares of its common stock to be sold by existing shareholder KKR Genetic Disorder L.P.. BridgeBio is not issuing any shares in this transaction and will not receive any offering proceeds.
The offering is expected to close on August 17, 2026, subject to customary closing conditions. William Blair, Goldman Sachs & Co. LLC and KKR Capital Markets LLC are acting as joint book-running managers. The shares are being offered under an automatic shelf registration statement on Form S-3ASR filed with the SEC on July 24, 2026.
BridgeBio Pharma (Nasdaq: BBIO) announced the launch of a secondary public offering of 5,000,000 shares of its common stock to be sold by existing shareholder KKR Genetic Disorder L.P. The company is not selling any shares in this transaction and will not receive any proceeds.
William Blair, Goldman Sachs & Co. LLC and KKR are acting as joint book-running managers. The offering is being made under an automatic shelf registration statement on Form S-3ASR and remains subject to market and other conditions, with final terms to be disclosed in a prospectus supplement filed with the SEC.
BridgeBio Pharma (Nasdaq: BBIO) reported that on August 8, 2026, its board compensation committee approved equity inducement grants of restricted stock units to 56 new employees, covering an aggregate of 66,705 shares of common stock. One-fourth of each grant will vest on August 16, 2027, with the remaining shares vesting in equal quarterly installments thereafter, subject to continued employment. The awards were granted as inducements to employment under Nasdaq Listing Rule 5635(c)(4) and pursuant to a company plan adopted in November 2019 and amended in February and December 2023.